All In Biotech

Drug Trial Radar · NCT04125732

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris

Last checked: Nov 19, 2026Latest source record: Jan 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Jan 24, 2020

Primary completion

Jan 31, 2023

Study completion May 30, 2023

Sponsor

Lead sponsor
XyloCor Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).

Conditions

  • Coronary Artery Disease
  • Ischemia
  • Angina Refractory
  • Cardiovascular Diseases
  • Heart Diseases

Interventions

  • AdVEGFXC1Biological

    AdVEGFXC1 at one of 4 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Endpoint (adverse events)Time frame: 6 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Cardiology Research Associates

    Daytona Beach, Florida

  • University of Florida

    Gainesville, Florida

  • James A. Haley VA Medical Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota

  • Duke University

    Durham, North Carolina

  • The Christ Hospital / The Lindner Research Center

    Cincinnati, Ohio

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • Houston Methodist

    Houston, Texas

  • Texas Heart Institute

    Houston, Texas

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.